Immune checkpoint inhibitor therapy (anti- CTLA-4, PD-1 or PD-L1 antibodies) boosts the cytotoxic activity of tumour antigen-specific T cells and has revolutionized treatment and increased survival for a subset of cancers (292, 293). The gene discussed is CD274; the disease is neoplasm.